BIIB vs. AEP, TEVA, PNW, VRTX, REGN, GILD, ALNY, BMRN, NBIX, and INCY
Should you be buying Biogen stock or one of its competitors? The main competitors of Biogen include American Electric Power (AEP), Teva Pharmaceutical Industries (TEVA), Pinnacle West Capital (PNW), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), and Incyte (INCY).
Biogen (NASDAQ:BIIB) and American Electric Power (NASDAQ:AEP) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.
87.9% of Biogen shares are held by institutional investors. Comparatively, 75.2% of American Electric Power shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 0.1% of American Electric Power shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Biogen had 15 more articles in the media than American Electric Power. MarketBeat recorded 33 mentions for Biogen and 18 mentions for American Electric Power. American Electric Power's average media sentiment score of 1.07 beat Biogen's score of 0.17 indicating that American Electric Power is being referred to more favorably in the news media.
American Electric Power has higher revenue and earnings than Biogen. American Electric Power is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Biogen currently has a consensus price target of $286.50, suggesting a potential upside of 27.09%. American Electric Power has a consensus price target of $88.92, suggesting a potential upside of 0.71%. Given Biogen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biogen is more favorable than American Electric Power.
American Electric Power has a net margin of 14.60% compared to Biogen's net margin of 12.07%. Biogen's return on equity of 14.83% beat American Electric Power's return on equity.
Biogen has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, American Electric Power has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.
Biogen received 1701 more outperform votes than American Electric Power when rated by MarketBeat users. Likewise, 71.94% of users gave Biogen an outperform vote while only 55.32% of users gave American Electric Power an outperform vote.
Summary
Biogen beats American Electric Power on 13 of the 18 factors compared between the two stocks.
Get Biogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
